Navigation Links
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
Date:8/5/2008

ipitor(R) (atorvastatin), Crestor(R) (rosuvastatin), Viagra(R) (sildenafil), Cialis(R) (tadalafil), Levitra(R) (vardenafil), oral contraceptives ("the pill") or the contraceptive patch, Mycobutin(R) (rifabutin), inhaled Flonase(R) (fluticasone), metronidazole, or disulfiram. Patients should talk with their doctor about all medicines they are taking or planning to take, including those without a prescription and herbal products.

KALETRA should not be given once-daily in combination with Sustiva(R) (efavirenz), Viramune(R) (nevirapine), Agenerase(R) (amprenavir), fosamprenavir, Viracept(R) (nelfinavir), phenobarbital, Dilantin(R) (phenytoin) or Tegretol(R) carbamazepine.

Patients and/or their care providers should pay special attention to accurate administration of the KALETRA dose to reduce the risk of accidentally giving too much or too little medicine.

The most commonly reported side effects of moderate severity that are thought to be drug related are abdominal pain, abnormal bowel movements, diarrhea, feeling weak/tired, headache and nausea. Children taking KALETRA may sometimes get a skin rash. Other side effects may occur.

Pancreatitis and liver problems, which can be fatal, have been reported in patients receiving KALETRA. Patients should tell their doctor if they have nausea, vomiting, or abdominal pain, which may be signs of pancreatitis, or if they have or have had liver disease, such as hepatitis B or C.

Some patients have had large increases in triglycerides and cholesterol. Changes in body fat have been seen in some patients taking anti-HIV therapy. The long-term health effects of these conditions are not known at this time.

Diabetes and high blood sugar have occurred in patients taking protease inhibitors, such as KALETRA.

Some patients with hemophilia have increased bleeding with protease inhibitors.

The effects of KALETRA on pregnant women or their unborn babies are not known. Mothers taking KALET
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
2. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
3. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
4. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
5. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
6. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
7. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
8. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
9. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
10. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
11. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)...tatistical significance , , ISELIN, N.J., N...ion (Nasdaq: PARS ) today announced results from...ulsion (NE) drug delivery technology formulated wi...lti-center, randomized, double-blinded, placebo-co...f the Company,s 3% Diclofenac Diethanolamine NanoE...
(Date:11/18/2008)...stCall/ -- NeuroDiscovery Ltd (ASX:,NDL), a speci...pment Company,and Sosei Group Corporation ("Sose...onal biopharmaceutical company, today announce tha...e-clinical efficacy data for NSL-043/SD118.,This ...uropathic pain and has,successfully completed Pha...
(Date:11/18/2008)...diagnosed, elderly AML patients , , PRINCET...uticals today announced that the first patient has...dy of CPX-351 (Cytarabine:Daunorubicin) Liposome I...eloid leukemia (AML). , , The first patient...dical College of Cornell University and New York ...
(Date:11/12/2008)...D. Watson, Marilyn & James Simons and,Sherry Lansi...ov. 12 J. Craig Venter,...er Institute (JCVI), was,awarded the Double Helix ...,November 6th at a gala event in New York City., ...ith Dr. James D.,Watson for making each of their i...
Breaking Medicine Technology:Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory 2Pulmo BioTech Announces Appointment of Chief Financial Officer 5069 1Pulmo BioTech Announces Appointment of Chief Financial Officer 5069 2Pulmo BioTech Announces Appointment of Chief Financial Officer 5069 3Got Fat 3F 3A Plastic Surgeons Review Fat Melting and Fat Grafting Procedures 1960 1Got Fat 3F 3A Plastic Surgeons Review Fat Melting and Fat Grafting Procedures 1960 2Got Fat 3F 3A Plastic Surgeons Review Fat Melting and Fat Grafting Procedures 1960 3Environmental fate of nanoparticles depends on properties of water carrying them 3161 1Environmental fate of nanoparticles depends on properties of water carrying them 3161 2Environmental fate of nanoparticles depends on properties of water carrying them 3161 3Thermage a Leading Aesthetic Medical Device Company Announces First Time Exhibitor Status at ACOG Meeting 18263 1Thermage a Leading Aesthetic Medical Device Company Announces First Time Exhibitor Status at ACOG Meeting 18263 2Thermage a Leading Aesthetic Medical Device Company Announces First Time Exhibitor Status at ACOG Meeting 18263 3
(Date:11/21/2008)...008)The University of Texas Health Science Center ...ellence in Aging Studies (TEXAS), to promote geria...s $2 million award from the Donald W. Reynolds Fou...is will allow us to teach geriatric medicine princ...dent to practicing physicians. With the reach of L...
(Date:11/21/2008)...ain cautious about future antibiotic resistance fr...(HealthDay News) -- People with moderate to severe...be able to reduce the frequency of exacerbations t... a new report says. , The study, published in ...nal of Respiratory and Critical Care Medicine , fo...
(Date:11/21/2008)...21 NursingCenter.com, the premier ...peer reviewed content, has been,updated to improv...tered,users. Powered by Lippincott Williams &...er 900 peer-reviewed continuing education activiti...han 50 leading nursing journals.,Lippincott Willi...
(Date:11/21/2008).... 21 Barr Pharmaceutical...areholders overwhelmingly approved the proposals s...rr by Teva Pharmaceuticals Industries Ltd. (Nasdaq... the overwhelming support of the transaction by th... Chairman and CEO. "We are pleased with the progre...
Breaking Medicine News(10 mins):Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4
...has been tons of information circulating around do...ign has asked donor-conceived parents to speak to ...ities were flooded with inquiries in this regard. ...lls and emails from parents of donor-conceived chi...
...bad-based Dishman Pharmaceuticals and Chemicals Lt...rvices business of US-based Solutia Inc for 74.5 m...ement for purchasing 100 per cent stake in CarboGe... pharmaceutical services division, Dishman said in...
...ng a decrease in the child mortality rate from 86 ...lans to bring it down further by earmarking Rs 2.6...ildren. // The benefits reaching women and childr... to all and the government will spend Rs 2.63 cror...
...sing serious concern over growing problems due to ...Social Justice and Empowerment Meira Kumar today s...tems in the region to check it. There is a need to...ng and reporting systems for all seven-sister stat...
Other Medicine News:
...The ACCU-Beam® line of Surgical Microscope Acc...litters, objective lenses, fiber optic cables, and...e Dual Adaptor allows the surgeon to document proc...eo or 35mm photography. Many different types of ad...
...The ACCU-Beam® line of Surgical Microscope Acc...litters, objective lenses, fiber optic cables, and...ersal Microsurgical Video Adaptor (US pat. no. 5,2...both single-chip and 3CCD cameras on the same adap...
...ALLEGRO Topolyzer and T-CAT have been optimized to...rection and to interact in perfect synchronization...ll necessary treatment and patient parameters are ...GRETTO WAVE laser systems via diskette, mini CD or...
...The WaveScan WaveFront System is an ophthalmic dia...ror and wavefront aberrations of the human eye usi...ents can be used to determine regular (sphero-cyli...rrations) that cause decreased or blurry vision in...
Medicine Products: